Feb 1 (Reuters) - KNIGHT THERAPEUTICS Inc GUD.TO :
* Press release - Braeburn Pharmaceuticals and Knight Therapeutics announce
Canadian sublicense agreement for probuphine
* Says under the terms Knight will also handle all ongoing regulatory and
commercial activities for probuphine in Canada
* Knight Therapeutics-co and Braeburn Pharmaceuticals entered into agreement
whereby co received exclusive rights to commercialize probuphine in Canada
* Source text for Eikon ID:nPn7ZRxF6
* Further company coverage GUD.TO